In: Obesity

Semaglutide liquid emulsion not checked

Gila Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Next date
Phase 4 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Obesity & Overweight
Main trialPhase 4
“This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.”In the company’s words, NCT07728383 on ClinicalTrials.gov

Other drugs for Obesity & Overweight

All 159 drugs for Obesity & Overweight

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 4Recruiting May 2027 A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow Semaglutide liquid emulsion

Following is part of Solo: you see every change to Semaglutide liquid emulsion the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in